Piper Sandler Boosts Kymera Therapeutics (NASDAQ:KYMR) Price Target to $140.00

Kymera Therapeutics (NASDAQ:KYMR) had its price objective hoisted by equities researchers at Piper Sandler from $125.00 to $140.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler’s price target suggests a potential upside of 56.75% from the company’s previous close.

Several other brokerages have also recently issued reports on KYMR. Royal Bank Of Canada upped their price objective on Kymera Therapeutics from $70.00 to $103.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Mizuho boosted their price target on shares of Kymera Therapeutics from $81.00 to $120.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. UBS Group raised shares of Kymera Therapeutics to a “strong-buy” rating in a research note on Thursday, December 4th. Guggenheim assumed coverage on shares of Kymera Therapeutics in a research note on Monday, November 3rd. They issued a “buy” rating and a $90.00 price objective for the company. Finally, Jefferies Financial Group boosted their target price on shares of Kymera Therapeutics from $73.00 to $122.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $117.75.

Kymera Therapeutics Stock Down 1.5%

NASDAQ KYMR traded down $1.37 during trading hours on Thursday, reaching $89.31. The company’s stock had a trading volume of 442,750 shares, compared to its average volume of 761,862. Kymera Therapeutics has a 1 year low of $19.44 and a 1 year high of $103.00. The company has a market capitalization of $6.43 billion, a price-to-earnings ratio of -24.98 and a beta of 2.21. The firm’s 50-day moving average price is $78.07 and its 200-day moving average price is $64.68.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. The company had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. During the same quarter in the previous year, the business earned ($0.88) EPS. The company’s quarterly revenue was down 60.8% on a year-over-year basis. Equities research analysts anticipate that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Transactions at Kymera Therapeutics

In related news, CEO Nello Mainolfi sold 100,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $89.17, for a total value of $8,917,000.00. Following the transaction, the chief executive officer owned 660,482 shares of the company’s stock, valued at $58,895,179.94. This trade represents a 13.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bruce Booth sold 229,809 shares of Kymera Therapeutics stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $91.73, for a total value of $21,080,379.57. Following the sale, the director directly owned 686,477 shares of the company’s stock, valued at approximately $62,970,535.21. This trade represents a 25.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 450,895 shares of company stock valued at $40,486,151. Company insiders own 16.01% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in KYMR. PNC Financial Services Group Inc. lifted its stake in shares of Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after buying an additional 770 shares during the period. Smartleaf Asset Management LLC increased its holdings in shares of Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares during the period. Larson Financial Group LLC increased its holdings in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after purchasing an additional 349 shares during the period. Osaic Holdings Inc. raised its stake in shares of Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the last quarter. Finally, Bessemer Group Inc. lifted its holdings in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after purchasing an additional 815 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.